CY1123996T1 - Υποκατεστημενα παραγωγα οξοπυριδινης - Google Patents
Υποκατεστημενα παραγωγα οξοπυριδινηςInfo
- Publication number
- CY1123996T1 CY1123996T1 CY20211100269T CY211100269T CY1123996T1 CY 1123996 T1 CY1123996 T1 CY 1123996T1 CY 20211100269 T CY20211100269 T CY 20211100269T CY 211100269 T CY211100269 T CY 211100269T CY 1123996 T1 CY1123996 T1 CY 1123996T1
- Authority
- CY
- Cyprus
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- disorders
- substituted
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Η εφεύρεση αφορά υποκατεστημένα παράγωγα οξοπυριδίνης και διεργασίες για την παρασκευή τους, και επίσης τη χρήση αυτών για την παρασκευή φαρμάκων για τη θεραπευτική αγωγή ή/και προφύλαξη ασθενειών, συγκεκριμένα καρδιαγγειακών διαταραχών, κατά προτίμηση θρομβωτικών ή θρομβοεμβολικών διαταραχών, και οιδημάτων, και επίσης οφθαλμικών διαταραχών.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176099 | 2015-07-09 | ||
| EP16157350 | 2016-02-25 | ||
| PCT/EP2016/065787 WO2017005725A1 (en) | 2015-07-09 | 2016-07-05 | Substituted oxopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123996T1 true CY1123996T1 (el) | 2022-07-22 |
Family
ID=56345141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100269T CY1123996T1 (el) | 2015-07-09 | 2021-03-26 | Υποκατεστημενα παραγωγα οξοπυριδινης |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US10421742B2 (el) |
| EP (1) | EP3319956B1 (el) |
| JP (1) | JP6871180B2 (el) |
| KR (1) | KR102596164B1 (el) |
| CN (2) | CN108026072B (el) |
| AU (1) | AU2016289746B2 (el) |
| CA (1) | CA2990901A1 (el) |
| CL (1) | CL2018000039A1 (el) |
| CO (1) | CO2018000113A2 (el) |
| CR (1) | CR20180017A (el) |
| CU (1) | CU24512B1 (el) |
| CY (1) | CY1123996T1 (el) |
| DK (1) | DK3319956T3 (el) |
| DO (1) | DOP2018000004A (el) |
| EA (1) | EA036208B1 (el) |
| EC (1) | ECSP18001308A (el) |
| ES (1) | ES2856554T3 (el) |
| GE (1) | GEP20197046B (el) |
| HK (1) | HK1255045A1 (el) |
| HR (1) | HRP20210459T1 (el) |
| HU (1) | HUE053552T2 (el) |
| IL (1) | IL256556B (el) |
| JO (1) | JO3703B1 (el) |
| LT (1) | LT3319956T (el) |
| MA (1) | MA42376B1 (el) |
| MX (1) | MX2018000076A (el) |
| MY (1) | MY196640A (el) |
| NI (1) | NI201800001A (el) |
| PE (1) | PE20180538A1 (el) |
| PH (1) | PH12018500057A1 (el) |
| PL (1) | PL3319956T3 (el) |
| RS (1) | RS61584B1 (el) |
| SI (1) | SI3319956T1 (el) |
| SV (1) | SV2018005610A (el) |
| TN (1) | TN2018000011A1 (el) |
| TW (1) | TWI717367B (el) |
| UA (1) | UA122341C2 (el) |
| UY (1) | UY36780A (el) |
| WO (1) | WO2017005725A1 (el) |
| ZA (1) | ZA201800826B (el) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2722423T3 (es) * | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| WO2016146606A1 (de) * | 2015-03-19 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose |
| WO2018041122A1 (zh) | 2016-08-31 | 2018-03-08 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| EP3889147A1 (en) | 2018-03-15 | 2021-10-06 | Bayer Aktiengesellschaft | 4-({(2s)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2h)-yl]butanoyl}-amino)-2-fluorobenzamide acetone and its use |
| DK3774796T3 (da) | 2018-04-10 | 2022-07-18 | Bayer Pharma AG | Et substitueret oxopyridinderivat |
| JP2021529201A (ja) | 2018-07-02 | 2021-10-28 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | オキシピリジンアミド誘導体の結晶形およびその調製方法 |
| AR115870A1 (es) | 2018-07-31 | 2021-03-10 | Sumitomo Chemical Co | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ |
| EP3898611A1 (en) * | 2018-12-17 | 2021-10-27 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications |
| MA54521A (fr) | 2018-12-21 | 2022-03-30 | Bayer Ag | Dérivés d'oxopyridine substitués |
| CA3124296A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
| CA3152667A1 (en) * | 2019-09-27 | 2021-04-01 | Shenzhen Salubris Pharmaceuticals Co. Ltd. | Fxia inhibitors and preparation method therefor and pharmaceutical use thereof |
| WO2022057849A1 (zh) | 2020-09-17 | 2022-03-24 | 浙江海正药业股份有限公司 | 哌嗪类衍生物及其制备方法和用途 |
| CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CA3212645A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| JP2024508970A (ja) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形 |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| CN113666826B (zh) * | 2021-07-30 | 2024-03-26 | 五邑大学 | 一种芳基或杂芳基甲氧基化反应的方法 |
| WO2023174399A1 (zh) * | 2022-03-18 | 2023-09-21 | 苏州晶云药物科技股份有限公司 | 取代的氧代吡啶类衍生物的晶型及其制备方法 |
| CN116535392B (zh) * | 2023-06-26 | 2023-09-05 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物的制备方法及中间体和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6642252B2 (en) | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| EP1526131A1 (en) | 2003-10-22 | 2005-04-27 | Graffinity Pharmaceuticals Aktiengesellschaft | Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EA015942B1 (ru) | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
| IN2014CN04676A (el) | 2011-12-21 | 2015-09-18 | Ono Pharmaceutical Co | |
| GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| DK2880026T3 (en) * | 2012-08-03 | 2017-06-06 | Bristol Myers Squibb Co | DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS |
| WO2014159218A1 (en) | 2013-03-14 | 2014-10-02 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions |
| US9809545B2 (en) * | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| EP3024822B1 (de) | 2013-07-23 | 2017-05-03 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate und ihre verwendung als faktor xia und plasmakallikrein inhibitoren |
| US9765070B2 (en) | 2013-10-30 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| JP6464176B2 (ja) | 2014-01-31 | 2019-02-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| WO2015120777A1 (zh) * | 2014-02-14 | 2015-08-20 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
| CA2961981A1 (en) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2694189T3 (es) * | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| ES2722423T3 (es) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| ES2716417T3 (es) | 2014-09-24 | 2019-06-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica |
| US10167280B2 (en) | 2014-09-24 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| JP6785838B2 (ja) * | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 新規な置換グリシン誘導のｆｘｉａ阻害剤 |
-
2016
- 2016-07-03 JO JOP/2016/0136A patent/JO3703B1/ar active
- 2016-07-05 CA CA2990901A patent/CA2990901A1/en active Pending
- 2016-07-05 PE PE2018000035A patent/PE20180538A1/es unknown
- 2016-07-05 LT LTEP16734672.5T patent/LT3319956T/lt unknown
- 2016-07-05 MX MX2018000076A patent/MX2018000076A/es unknown
- 2016-07-05 CU CU2018000001A patent/CU24512B1/es unknown
- 2016-07-05 JP JP2017568177A patent/JP6871180B2/ja active Active
- 2016-07-05 TN TNP/2018/000011A patent/TN2018000011A1/en unknown
- 2016-07-05 US US15/742,063 patent/US10421742B2/en active Active
- 2016-07-05 CR CR20180017A patent/CR20180017A/es unknown
- 2016-07-05 EA EA201890111A patent/EA036208B1/ru not_active IP Right Cessation
- 2016-07-05 MY MYPI2018700053A patent/MY196640A/en unknown
- 2016-07-05 DK DK16734672.5T patent/DK3319956T3/da active
- 2016-07-05 UA UAA201801270A patent/UA122341C2/uk unknown
- 2016-07-05 CN CN201680052335.5A patent/CN108026072B/zh active Active
- 2016-07-05 EP EP16734672.5A patent/EP3319956B1/en active Active
- 2016-07-05 HU HUE16734672A patent/HUE053552T2/hu unknown
- 2016-07-05 CN CN202110557164.4A patent/CN113292539B/zh active Active
- 2016-07-05 RS RS20210338A patent/RS61584B1/sr unknown
- 2016-07-05 WO PCT/EP2016/065787 patent/WO2017005725A1/en active Application Filing
- 2016-07-05 MA MA42376A patent/MA42376B1/fr unknown
- 2016-07-05 AU AU2016289746A patent/AU2016289746B2/en active Active
- 2016-07-05 ES ES16734672T patent/ES2856554T3/es active Active
- 2016-07-05 PL PL16734672T patent/PL3319956T3/pl unknown
- 2016-07-05 GE GEAP201614692A patent/GEP20197046B/en unknown
- 2016-07-05 SI SI201631060T patent/SI3319956T1/sl unknown
- 2016-07-05 KR KR1020187003576A patent/KR102596164B1/ko active IP Right Grant
- 2016-07-07 TW TW105121492A patent/TWI717367B/zh active
- 2016-07-08 UY UY0001036780A patent/UY36780A/es active IP Right Grant
-
2017
- 2017-12-25 IL IL256556A patent/IL256556B/en active IP Right Grant
-
2018
- 2018-01-04 NI NI201800001A patent/NI201800001A/es unknown
- 2018-01-05 DO DO2018000004A patent/DOP2018000004A/es unknown
- 2018-01-05 CL CL2018000039A patent/CL2018000039A1/es unknown
- 2018-01-05 PH PH12018500057A patent/PH12018500057A1/en unknown
- 2018-01-08 EC ECIEPI20181308A patent/ECSP18001308A/es unknown
- 2018-01-08 SV SV2018005610A patent/SV2018005610A/es unknown
- 2018-01-09 CO CONC2018/0000113A patent/CO2018000113A2/es unknown
- 2018-02-08 ZA ZA2018/00826A patent/ZA201800826B/en unknown
- 2018-11-07 HK HK18114169.6A patent/HK1255045A1/zh unknown
-
2019
- 2019-08-08 US US16/535,120 patent/US11180471B2/en active Active
-
2021
- 2021-03-18 HR HRP20210459TT patent/HRP20210459T1/hr unknown
- 2021-03-26 CY CY20211100269T patent/CY1123996T1/el unknown
- 2021-10-18 US US17/504,243 patent/US20230024752A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123996T1 (el) | Υποκατεστημενα παραγωγα οξοπυριδινης | |
| CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| NI201500143A (es) | Derivados de oxopiridinas sustituida y usos de los mismos en el tratamiento de trastornos cardivasculares. | |
| CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| EA201991997A1 (ru) | Комбинированная терапия | |
| CY1124492T1 (el) | 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| CY1123543T1 (el) | Παραγωγα διαμινοπυριδινης | |
| IT201600103956A1 (it) | Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| TR201819920T4 (tr) | Kuru göz sendromunun tedavisinde kullanım için oftalmik bileşimler. | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| EA201501176A1 (ru) | Замещенные бензоксазолы | |
| CY1121388T1 (el) | Παραγωγα βενζυλυδροξειδιου, παρασκευη αυτων και θεραπευτικη χρηση αυτων |